{"url_path":"/sec/silo/8-k/2026-06-03/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-064804-index.html","accession_number":"0001213900-26-064804","cik":"0001514183","ticker":"SILO","issuer_name":"Silo Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-064804-index.html","primary_entity_key":"0001514183","primary_entity_name":"Silo Pharma, Inc."},"word_count":207,"has_tables":true,"body_markdown":"**Item 8.01. Other Events.**\n\n \n\nThe information contained\nin Item 5.03 of this report is incorporated herein by reference.\n\n \n\nThe Company has a registration\nstatements on Form S-1 (File Nos. 333-280855 and 333-291129) and a registration statements on Form S-3 (File Nos. 333-276658) on file\nwith the SEC. SEC regulations permit the Company to incorporate by reference future filings made with the SEC pursuant to Sections 13(a),\n13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the termination of the offerings covered by registration\nstatements filed on Form S-3 or Form S-8. The information incorporated by reference is considered to be part of the prospectus included\nwithin each of those registration statements. Information in this Item 8.01 of this report is therefore intended to be automatically incorporated\nby reference into each of the active registration statements listed above, thereby amending them. Pursuant to Rule 416(b) under the Securities\nAct of 1933, as amended, the amount of undistributed shares of Common Stock deemed to be covered by the effective registration statements\nof the Company described above are proportionately reduced as of the effective time of the Reverse Stock Split at the 1-15 Reverse Stock\nSplit ratio, giving effect to the Reverse Stock Split."}